Researchers at Moffitt Cancer Center and colleagues have found that adolescents newly diagnosed with cancer have strong concerns about their ability to have children as cancer survivors. They also found that standard health-related quality-of-life survey tools used to elicit answers from teens with cancer did not accurately reflect these concerns. Parents, who often answer survey questions as proxies, often inaccurately relayed their child's reproductive concerns. The study, carried out by Moffitt researchers and colleagues from the University of South Florida, the University of Florida, All Children's Hospital and Children's Hospital of Orange County Children's Cancer Institute (Orange, Calif.) was published in a recent issue of PEDIATRICS (129:4). The study was funded by National Institutes of Health grants UL1 DE19587 and UL1 DE019587.
Glioblastoma is the most prevalent and deadliest type of brain cancer, and each year around 10, 000 individuals in the U.S. are diagnosed with the disease. Now, researchers have found a protein that may provide insight into how the disease moves and invades nearby healthy brain tissue. In addition, the researchers suggest that a cost-effective FDA-approved drug already on the market could slow movement of these deadly cancer cells. The study is published May 1 in the online, open-access journal PloS Biology. Lead author of the study, Alfredo Quinones-Hinojosa, M.D., an associate professor of neurosurgery and oncology at the Johns Hopkins University School of Medicine, explains: "The biggest challenge in brain cancer is the migration of cancer cells. We can't control it. If we could catch these cells before they take off into other parts of the brain, we could make malignant tumors more manageable, and improve life expectancy and quality of life.
If you are a cancer survivor and you want to minimize your risk of that cancer recurring, or another cancer developing, you should eat a healthy diet, do plenty of exercise, and maintain a healthy body weight, says the American Cancer Society in its new guidelines. Colleen Doyle, MS, RD, Director of Nutrition and Physical Activity at the American Cancer Society, and co-author of the guidelines, says most of the recommendations come down to common sense and have been around for many years. Doyle explained that while working for the American Cancer society, many people have come up to her with questions regarding their present, past and future health. The three most common questions have been: "How can I minimize the chances of my cancer recurring?" "How can I minimize my chances of developing some other cancer?
A brand new type of epigenetic cancer pill has been deemed safe for use in a Phase I trial according to Clinical Cancer Research. Epigenetics is the study of heritable changes in gene expression or cellular phenotype caused by mechanisms other than changes in the underlying DNA sequence, which refers to functionally relevant modifications to the genome that do not involve a change in the nucleotide sequence. Epigenetics play many different roles in nature, for instance the ability of a caterpillar to morph into a butterfly without changing its DNA. The drug, a collaboration of The Institute of Cancer Research (ICR) and Chroma Therapeutics, is aimed at errors that cause cancer in the way the body reads the DNA code, instead of targeting the faults in the DNA code. Reading cancer-causing errors in the way the body reads the DNA code is a very significant set of instructions, that focuses on a number of chemical switches, which determine whether or not genes are switched on or off and ultimately determines the cell's function and its appearance.
According to a study published in Nature Genetics, an international team of researchers have identified mutations in two regions of the genome that increase the risk of developing Wilms tumor. Wilms tumor is the most prevalent type of kidney cancer in children and usually develops before the age of five. The disease affects around 1 in 10, 000 children and has a 90% cure rate. In the majority of children researchers are unsure as to what causes the tumor although they know that genes play a role. In this study, the researchers report on the first scan of common mutations in the genomes of Wilms tumor patients. The researchers used a genome wide association study in order to compare common DNA mutations in the genetic code of nearly 1, 500 Wilms tumor patients with variants in 3, 850 healthy individuals in the UK and the United States.